Posted by Michael Wonder on 11 Sep 2024
Neuraptive Therapeutics receives FDA breakthrough therapy designation for NTX-001
11 September 2024 - Neuraptive Therapeutics today announced that NTX-001 has been granted breakthrough therapy designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair.
This designation follows the results from the Phase 2 NEUROFUSE study and several interactions with the FDA. NTX-001 has the potential to be a groundbreaking therapy in the field of nerve repair.
